BR100 Increased By (0.16%)
BR30 Increased By (0.03%)
KSE100 Increased By (0.19%)
KSE30 Increased By (0.23%)
AGHA 6.77 Increased By ▲ 0.09 (1.35%)
BECO 4.40 Increased By ▲ 0.03 (0.69%)
BML 56.50 Decreased By ▼ -0.82 (-1.43%)
BOP 30.47 Increased By ▲ 0.12 (0.4%)
CNERGY 13.13 Increased By ▲ 0.01 (0.08%)
CSIL 5.44 Increased By ▲ 0.03 (0.55%)
FCCL 52.96 Increased By ▲ 0.17 (0.32%)
FFL 14.82 Increased By ▲ 0.10 (0.68%)
FNEL 1.13 Increased By ▲ 0.01 (0.89%)
KEL 6.13 Increased By ▲ 0.04 (0.66%)
KOSM 5.85 Increased By ▲ 0.12 (2.09%)
LOTCHEM 26.64 Increased By ▲ 0.18 (0.68%)
MLCF 93.60 Increased By ▲ 0.44 (0.47%)
NBP 165.00 Increased By ▲ 0.34 (0.21%)
NCPL 55.75 Increased By ▲ 0.09 (0.16%)
NPL 61.29 Increased By ▲ 0.13 (0.21%)
OGDC 315.70 Decreased By ▼ -1.03 (-0.33%)
PACE 9.96 Increased By ▲ 0.09 (0.91%)
PAEL 35.65 Increased By ▲ 0.02 (0.06%)
PIBTL 14.99 Increased By ▲ 0.31 (2.11%)
PPL 225.75 Decreased By ▼ -1.16 (-0.51%)
PRL 93.40 Increased By ▲ 0.38 (0.41%)
PTC 60.44 Increased By ▲ 0.18 (0.3%)
SSGC 23.86 Increased By ▲ 0.05 (0.21%)
TBL 8.82 Increased By ▲ 0.07 (0.8%)
TELE 7.86 Increased By ▲ 0.06 (0.77%)
TPL 22.64 Increased By ▲ 0.29 (1.3%)
TPLP 12.97 No Change ▼ 0.00 (0%)
TREET 22.31 Increased By ▲ 0.15 (0.68%)
TRG 56.93 Increased By ▲ 0.37 (0.65%)
By

GENEVA: The AstraZeneca-Oxford Covid-19 vaccine can be used for people aged over 65, and also where coronavirus variants of concern are circulating, WHO experts said Wednesday, soothing fears about the jab.

The World Health Organization’s 15-member Strategic Advisory Group of Experts on Immunization (SAGE) issued interim recommendations for when and how to use the two-shot vaccine, which has yet to receive WHO emergency use authorisation.

The announcement came after the vaccine suffered several setbacks, raising questions about whether it was appropriate to use it on older people, or in places where a variant of the virus first found in South Africa is circulating.

SAGE chief Alejandro Cravioto acknowledged the lack of data on the vaccine’s efficacy for people aged over 65, which has prompted a number of countries to withhold recommending its use in older people — who are by far the most vulnerable to the virus.

But, he told journalists, “we feel that the response of this group cannot be any different from groups of a younger age”.

SAGE, he said, recommends “for the vaccine to be used for 18 years and above without an upper age limit”.

He said the experts were eagerly awaiting more specific data on the efficacy of the vaccine in people over 65, but said it “would not be appropriate” to wait with its recommendations.

“We have thousands of people dying,” he stressed.

Comments

Comments are closed for this article.